Moneycontrol PRO
HomeNewsBusinessMarketsSuven Pharma zooms 12% on merger with Cohance Lifesciences

Suven Pharma zooms 12% on merger with Cohance Lifesciences

Suven Pharmaceuticals Limited on February 29 announced a scheme of amalgamation for merger with Cohance Lifesciences Limited

March 01, 2024 / 13:53 IST
The merged entity is expected to be amongst leading integrated CDMO players in India. With an expanded capacity to around 2,650 kL and a significantly broadened customer base, scale and synergy benefits are substantial.

The merged entity is expected to be amongst leading integrated CDMO players in India. With an expanded capacity to around 2,650 kL and a significantly broadened customer base, scale and synergy benefits are substantial.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Suven Pharma jumped 12 percent in morning deals on March 1 , a day after the firm announced a scheme of amalgamation for a merger with Cohance Lifesciences.

The transaction is expected to conclude over next the 12-15 months, subject to shareholder and regulatory approvals, the company said in a release.

Cohance is a contract development and manufacturing organisation (CDMO) and merchant Active Pharmaceutical Ingredient (API) platform with global leadership in select low-mid volume molecules as well as unique capabilities in the form of its antibody-drug conjugates (ADC) platform.

Follow our market blog to catch all the live action

On February 7, 2024, Moneycontrol was the first to report that leading global private equity fund Advent International had initiated the merger process for its portfolio companies Suven Pharmaceuticals and Cohance Lifesciences and picked Kotak Mahindra Capital and Citi as advisors for deal aspects like swap ratio, due diligence and fairness opinion.

The merger will establish Suven as a diversified CDMO and API leader in India, expnnding its revenue base, the company told exchanges. The merged entity is expected to be amongst the leading integrated CDMO players in India.

With an expanded capacity of 2,650 kL and a significantly broadened customer base, scale and synergy benefits would be substantial.

Upon the scheme becoming effective, all shareholders of Cohance will be issued shares of Suven in the ratio of 11 shares of Suven for every 295 shares of Cohance, based on the swap ratio. The new shares of Suven will trade on NSE as well as BSE.

Advent will own 66.7 percent and the public shareholders will hold 33.3 percent of the combined entity (pre-ESOP dilution).

Also Read | Suven Pharma, Cohance Lifesciences announce merger

At 10.13 am, Suven Pharma shares were trading nearly 10 percent higher at Rs 694.55 on the National Stock Exchange. In the last year, the stock has jumped around 45 percent against as a 27 percent rise in the Nifty.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Moneycontrol News
first published: Mar 1, 2024 10:31 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347